ASND (ASND) Stock Price & Analysis
ASND (ASND) rose 3.61% to USD 213.23 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
ASND last closed at USD 205.81; the session ranged USD 204.3–215.44 on volume of 461,601 shares. Market capitalization is $13.17B, with a 52-week range of USD 160.86–250.74 (NMS). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 213.23 |
|---|---|
| Change | ▲ 3.61% (up) |
| Previous Close | USD 205.81 |
| Open | USD 207.33 |
| Day Range | USD 204.3 – 215.44 |
| 52-Week Range | USD 160.86 – 250.74 |
| Volume | 461,601 shares |
| Market Cap | $13.17B |
| Exchange | NMS |
Technical Analysis (ASND)
Nexqual's technical model rates ASND "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.17 (neutral) |
| vs SMA50 | Below (USD 232.26) |
| MACD | -6.35 (negative) |
Analyst Ratings (ASND)
Wall Street analysts rate ASND "Strong Buy" based on 17 analysts, with a mean price target of USD 295.49 (range USD 250.95–351.93), per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 295.49 |
| High Target | USD 351.93 |
| Low Target | USD 250.95 |
| Buy / Hold / Sell | 17 / 0 / 0 |
Earnings (ASND)
| Next Earnings Date | 2026-04-30 |
|---|---|
| EPS Estimate | USD 0.7 |
| Revenue Estimate | $331.97M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.27 vs est -0.08 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (ASND)
| Total Revenue | $865.78M |
|---|---|
| Revenue Growth (YoY) | +144.30% |
| Gross Margin | +89.04% |
| Operating Margin | +10.06% |
| Profit Margin | +57.28% |
| ROE | +332.65% |
| Debt / Equity | 183.75 |
| Current Ratio | 1 |
| Total Cash | $572.82M |
| Total Debt | $896.66M |
| Free Cash Flow | $118.23M |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (ASND)
Nexqual rates ASND's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Strong — Revenue +98% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 89%, operating 10% |
| Balance Sheet | Critical — $573M cash vs $897M debt |
| Cash Flow | Strong — FCF $118M, 16% margin |
| Efficiency | Strong — ROE 333%, ROA -0.6% |
Ownership (ASND)
| Insider Ownership | +0.82% |
|---|---|
| Institutional Ownership | +110.56% |
| Shares Outstanding | 61.78M |
| Float | 62.11M |
| Short % of Float | +3.34% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Leadership (ASND)
ASND is led by Jan Moller Mikkelsen (age 65), President, CEO, Member of Executive Board & Executive Director, per Nexqual as of June 9, 2026 at 23:51 UTC.
| President, CEO, Member of Executive Board & Executive Director | Jan Moller Mikkelsen (age 65) |
|---|---|
| CFO, Executive VP & Member of Executive Board | Scott T. Smith (age 51) |
| Vice President of Investor Relations | Chad Fugure |
| Executive Vice President of Product Supply & Quality | Flemming Steen Jensen (age 64) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ARGX | argenx SE | USD 884 | ▼ 0.82% |
| RARE | Ultragenyx Pharmaceutical Inc. | USD 22.79 | ▲ 4.02% |
| KRYS | Krystal Biotech, Inc. | USD 309.75 | ▲ 2.91% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 476.89 | ▼ 2.07% |
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.